The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...